Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04936997 · ClinicalTrials.gov registry record · Early Phase 1

Immune Response to the COVID-19 Vaccine

A Early Phase 1 study, sponsored by University of Arizona.

Completed
Registry status
Early Phase 1
Development phase
20
Enrollment target

NCT04936997 is a Early Phase 1 study that has completed, run by University of Arizona. The registered enrollment target is 20 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04936997, a Early Phase 1 study, has completed, sponsored by University of Arizona.

COMPLETED
Registry status
Early Phase 1
Development phase
20 participants
Enrollment target

Study Summary

Explore the effects on immune response to include a potential third vaccine for the cancer cohort.

Interventions

  • BIOLOGICAL SARS-COV2 Pfizer Vaccine

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2021-06-07
Est. Completion 2022-05-08
Phase Early Phase 1

Sponsor

University of Arizona

349 total trials

What the Registry Record Tells You About NCT04936997

The ClinicalTrials.gov registry entry for NCT04936997 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which SARS-COV2 Pfizer Vaccine is the first listed.

NCT04936997 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04936997 about?

NCT04936997 is a clinical study titled "Immune Response to the COVID-19 Vaccine". Explore the effects on immune response to include a potential third vaccine for the cancer cohort.

What is the current status of trial NCT04936997?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2021-06-07. Estimated completion is 2022-05-08.

What interventions are being tested in trial NCT04936997?

The interventions under investigation include: SARS-COV2 Pfizer Vaccine (BIOLOGICAL).

Who is sponsoring clinical trial NCT04936997?

This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.